Abstract
SARS-CoV-2 is an embryonic pathogen known to be the primary cause of coronavirus diseases that originated in China in 2019 (COVID -19). Since SARS-CoV-2 emerged in late 2019, the disease has accomplished epidemic proportions causing surging illness and death worldwide. SARS-CoV-2 has varying life-threatening complications, which makes it challenging to deal with the embryonic pathogen. Platelets are significant effectors cells of hemostasis and compulsive thrombosis. Consequently, platelets' engagement in the pathogenesis of the global pandemic SARS-CoV-2, commonly referred to as coronavirus or COVID-19, remains intense. The article discusses the increasing platelet activation observed in severe patients of COVID-19. The recent update by the World Health Organization (WHO) reports that acquaintance to plasma from severe coronavirus patients increase controlling platelet activation.
In most cases, coronavirus victims with severe symptoms end up being admitted to an intensive care unit. Platelet activation makes patients under an intensive care unit supported with ventilators to help them breathe. Based on the noted COVID-19 cases observed across the globe, platelet activation is linked with coagulation exacerbation markers, making a patient develop severe symptoms which needs invasive mechanical ventilation or advanced life support medical equipment. Furthermore, this article notes that the severity of COVID -19 patients primarily depends on the underlying health conditions. Patients with underlying conditions such as hypertension are at high risk of developing severe symptoms, while COVID-19 patients with no underlying conditions may develop mild symptoms. Lastly, this article's research findings outline that platelets from severe COVID-19 patients can induce a patient's TF expressions, thus increasing the severity of the virus. The aggregate coronavirus cases reported in the article are not static because infection increases daily.
Delegate your assignment to our experts and they will do the rest.
References
Hottz, E. D., Azevedo-Quintanilha, I. G., Palhinha, L., Teixeira, L., Barreto, E. A., Pão, C. R., ... & Bozza, P. T. (2020). Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood, The Journal of the American Society of Hematology , 136 (11), 1330-1341.
